Literature DB >> 20640586

Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.

Akio Nakamura1, Ryo Niimi, Kumiko Kurosaki, Yukishige Yanagawa.   

Abstract

BACKGROUND: This study attempted to identify the cardiovascular risk factors associated with retention of excess weight following termination of glucocorticoid therapy in children with nephrotic syndrome.
METHODS: We performed a retrospective study of 30 Japanese children (18 males, 12 females, aged 1-14 years) who had been treated with glucocorticoids for steroid-sensitive nephrotic syndrome and 32 control children (17 males, 15 females, aged 1-15 years). The subjects receiving glucocorticoid therapy were divided into a retention group (n = 14) or a reduction group (n = 16) on the basis of the presence or absence of a maintained body mass index (BMI) following glucocorticoid termination. BMI z-scores, age, gender, blood pressure, serum total cholesterol levels (T-cho), and the dose and duration of glucocorticoid exposure were evaluated in each group during the study period.
RESULTS: The retention group had a significantly (P < 0.05) increased dose and duration of glucocorticoid exposure, and of T-cho at the time of last visit compared with the control or reduction group. Moreover, logistic regression analysis showed that the adjusted odds ratio for T-cho at the time of last visit in the retention group was significantly higher (P < 0.05) relative to the reduction group.
CONCLUSION: Retention of excess weight during the period of remission from nephrotic syndrome following cessation of glucocorticoid therapy was related to the dose and duration of glucocorticoid exposure and was associated with hyperlipidemia, which might enhance cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20640586     DOI: 10.1007/s10157-010-0317-9

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  16 in total

Review 1.  Diagnosis and complications of Cushing's syndrome: a consensus statement.

Authors:  G Arnaldi; A Angeli; A B Atkinson; X Bertagna; F Cavagnini; G P Chrousos; G A Fava; J W Findling; R C Gaillard; A B Grossman; B Kola; A Lacroix; T Mancini; F Mantero; J Newell-Price; L K Nieman; N Sonino; M L Vance; A Giustina; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

Review 2.  Overweight children and adolescents: description, epidemiology, and demographics.

Authors:  R P Troiano; K M Flegal
Journal:  Pediatrics       Date:  1998-03       Impact factor: 7.124

Review 3.  Prescription medications: a modifiable contributor to obesity.

Authors:  L J Cheskin; S J Bartlett; R Zayas; C H Twilley; D B Allison; C Contoreggi
Journal:  South Med J       Date:  1999-09       Impact factor: 0.954

4.  Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children.

Authors: 
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

5.  A simple estimate of glomerular filtration rate in adolescent boys.

Authors:  G J Schwartz; B Gauthier
Journal:  J Pediatr       Date:  1985-03       Impact factor: 4.406

Review 6.  Tissue glucocorticoid resistance/hypersensitivity syndromes.

Authors:  Tomoshige Kino; Massimo U De Martino; Evangelia Charmandari; Marco Mirani; George P Chrousos
Journal:  J Steroid Biochem Mol Biol       Date:  2003-06       Impact factor: 4.292

7.  Corticosteroid therapy-induced obesity in children.

Authors:  R J Merritt; S L Hack; M Kalsch; D Olson
Journal:  Clin Pediatr (Phila)       Date:  1986-03       Impact factor: 1.168

8.  Management of childhood onset nephrotic syndrome.

Authors:  Debbie S Gipson; Susan F Massengill; Lynne Yao; Shashi Nagaraj; William E Smoyer; John D Mahan; Delbert Wigfall; Paul Miles; Leslie Powell; Jen-Jar Lin; Howard Trachtman; Larry A Greenbaum
Journal:  Pediatrics       Date:  2009-07-27       Impact factor: 7.124

9.  Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome.

Authors:  Maria H Kniazewska; Anna K Obuchowicz; Tomasz Wielkoszyński; Joanna Zmudzińska-Kitczak; Katarzyna Urban; Marta Marek; Jolanta Witanowska; Karolina Sieroń-Stołtny
Journal:  Pediatr Nephrol       Date:  2008-10-30       Impact factor: 3.714

10.  Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome.

Authors:  R Tanaka; N Yoshikawa; Y Kitano; H Ito; H Nakamura
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

View more
  4 in total

1.  Augmentation index, a predictor of cardiovascular events, is increased in children and adolescents with primary nephrotic syndrome.

Authors:  Cláudia Alves; José Felippe Pinho; Luzia Maria Dos Santos; Giselle Magalhães; Júnia Maria da Silva; Fernanda Luiza Fontes; Sordaini Maria Caligiorne; Sérgio Pinheiro; Maria Glória Rodrigues-Machado
Journal:  Pediatr Nephrol       Date:  2019-12-16       Impact factor: 3.714

2.  Subclinical cardiovascular disease and its association with risk factors in children with steroid-resistant nephrotic syndrome.

Authors:  Cengiz Candan; Nur Canpolat; Selman Gökalp; Nurdan Yıldız; Pınar Turhan; Mehmet Taşdemir; Lale Sever; Salim Çalışkan
Journal:  Pediatr Nephrol       Date:  2013-09-15       Impact factor: 3.714

3.  Assessment of Carotid Intima Media Thickness and Left Ventricular Mass Index in Children with Idiopathic Nephrotic Syndrome.

Authors:  Heba Mostafa Ahmed; Emad El-Deen Ameen; Mohammad Shafiq Awad; Osama Ezzat Botrous
Journal:  Vasc Health Risk Manag       Date:  2021-06-10

4.  Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study).

Authors:  Rasmus Ehren; Marcus R Benz; Burkhard Toenshoff; Lutz T Weber; Jorg Doetsch; Alexander Fichtner; Jutta Gellermann; Dieter Haffner; Britta Höcker; Peter F Hoyer; Bärbel Kästner; Markus J Kemper; Martin Konrad; Steffen Luntz; Uwe Querfeld; Anja Sander
Journal:  BMJ Open       Date:  2018-10-10       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.